Full history for every metric is available with a Kvantra account

Stock profile

Psychemedics Corporation (PMD)

Country: United States of AmericaSector: HealthcareIndustry: Medical - Diagnostics & ResearchExchange: NASDAQ

Delisted · last close 10 Feb 2026

Current price
2.67 USD0.00%
Last close 10 Feb 2026
Benchmarks

Key financial summary

Financials in USD
201920202021202220232024TTM
Total revenue$m38212525222020
Operating profit$m-2-2
Net profit$m2-4-1-1-4-2-2
EPS reported$-0.32-0.32
Operating cashflow per share$0.160.16
Capex per share$0.010.01
FCF per share$0.140.14
Free cash flow$m11
Net debt$m-1-1
Book value equity$m55
Book value per share$0.870.87
Number of sharesm5.875.89
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
201920202021202220232024TTM
Value
P/E TTMx--
P/B LTMx2.563.03
P/S LTMx0.670.79
P/FCF LTMx15.6117.83
EV/EBITDA LTMx67.4975.16
EV/Sales LTMx0.650.73
Earnings Yield LTM%-14.16%-11.88%
FCF Yield%6.41%5.61%
Quality
ROE%-36.28%-31.54%
ROIC%-29.20%-29.20%
Operating margin%-9.62%-9.62%
Gross margin%36.07%36.07%
FCF/Sales%4.28%4.28%
Growth and momentum
EPS Growth YoY%--
Sales Growth YoY%-10.92%-10.92%
Net Income Growth YoY%--
FCF Growth%--
Operating Profit Growth%--
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%-100.00%0.00%
Payout Ratio%0.00%0.00%
FCF/Debtx0.720.75
Net Debt/EBITDAx-1.31-1.31
EBIT/Net interestx-72.81-72.81
Net debt/market cap%-9.19%-7.76%
Net debt/Equityx-0.24-0.24
Gross debt/equityx0.230.23

Company overview

Established in 1986 and based in Acton, Massachusetts, Psychemedics Corporation specializes in providing comprehensive drug abuse detection services. The company operates across the United States, Brazil, and various international locations, employing hair sample analysis to identify a broad spectrum of substances. Their rigorous testing methodology involves both initial screening and confirmatory analysis through mass spectrometry, adhering to recognized industry standards. Psychemedics' analytical capabilities cover a wide array of drugs, including common illicit substances like cocaine, marijuana, and PCP. They also detect various amphetamines, such as ecstasy, eve, and Adderall, along with a comprehensive list of opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. Furthermore, their tests identify synthetic cannabinoids (e.g., K2, Spice, Blaze), benzodiazepines (like Xanax, Valium, and Ativan), nicotine, and Fentanyl. The results of their analyses offer more than just a positive or negative finding; they provide quantitative data indicating the approximate amount of drug consumed. Crucially, the tests also yield historical information that can reveal an individual's drug use patterns over an extended period. Psychemedics serves a diverse clientele, including employers seeking applicant and employee drug screening, treatment professionals, law enforcement agencies, school administrators, and parents concerned about potential substance use by their children.

WebsiteN/A
IndustryMedical - Diagnostics & Research
Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Delisted · last close 10 Feb 2026

Psychemedics Corporation (PMD)

PMD · NASDAQ · Healthcare
2.67 USD0.00%
Benchmarks
Financialsin USD
20232024TTM
About

Established in 1986 and based in Acton, Massachusetts, Psychemedics Corporation specializes in providing comprehensive drug abuse detection services. The company operates across the United States, Brazil, and various international locations, employing hair sample analysis to identify a broad spectrum of substances. Their rigorous testing methodology involves both initial screening and confirmatory analysis through mass spectrometry, adhering to recognized industry standards. Psychemedics' analytical capabilities cover a wide array of drugs, including common illicit substances like cocaine, marijuana, and PCP. They also detect various amphetamines, such as ecstasy, eve, and Adderall, along with a comprehensive list of opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. Furthermore, their tests identify synthetic cannabinoids (e.g., K2, Spice, Blaze), benzodiazepines (like Xanax, Valium, and Ativan), nicotine, and Fentanyl. The results of their analyses offer more than just a positive or negative finding; they provide quantitative data indicating the approximate amount of drug consumed. Crucially, the tests also yield historical information that can reveal an individual's drug use patterns over an extended period. Psychemedics serves a diverse clientele, including employers seeking applicant and employee drug screening, treatment professionals, law enforcement agencies, school administrators, and parents concerned about potential substance use by their children.

IndustryMedical - Diagnostics & Research
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free